Result card

  • CUR5: What are the consequences of Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI) for the society (i.e. the burden of the disease)?
English

What are the consequences of Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI) for the society (i.e. the burden of the disease)?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

Alzheimer’s disease has great consequences not only for the patient and the family members, but also for the health care system and the society. The direct medical costs (hospital care, medication, visits to clinics) are highest in the Western Europe and North America, however, majority of the costs are related to direct social care costs (homecare, food services, residential and nursing home care) and  informal care (input of families) (CUR-5 Table 1). According to World bank data 42.3% of the total costs are direct social costs, 41.7% informal care and 16% direct medical costs {84}.

In the United Kingdom, the annual societal costs of dementia (£23 billion) were estimated to match those of cancer (£12 billion), heart disease (£8 billion) and stroke (£5 billion) combined {84}. Therefore early diagnosis and evidence-based interventions are in greater focus. Delaying the onset by just a year or two could reduce the burden of AD on society and health care system.

 

CUR-5 Table 1. Estimated number of people with dementia and prevalence of dementia in population > 60 years (2010) {65} and the burden of disease (in billions US$) by WHO {84}.

Region

People with dementia

Prevalence, crude 2010

Proportionate increase

2010-2050, %

Direct medical costs

Direct social care costs

Informal care costs (all ADLs)

Europe, Western

9,727

7.2

93

3,019

9,288

8,705

Europe, Central

2,361

4.7

91

267

294

859

Europe , Eastern

3,930

4.7

66

342

294

796

North America

6,367

6.9

151

3,683

9,745

7,876

Asia, East

17,161

3.2

311

433

284

1,524

North Africa, Middle east

3,111

3.7

438

205

0.54

190

World

75,854

4.7

225

9,641

25,569

25,189

Key: ADLs, activities of daily living.

Critical
Partially
Migliore A et al. Result Card CUR5 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References